Glaukos Corporation, a public ophthalmic medical technology company, was founded with the mission to pioneer novel treatments for chronic eye diseases. The company's core vision is to advance the global ophthalmic market by developing therapies that enhance the standard of care and improve patient outcomes. Glaukos offers a range of micro-scale injectable therapies targeting glaucoma, keratoconus, and retinal diseases. Their product portfolio includes innovative glaucoma treatments, corneal cross-linking interventions for keratoconus, and sustained-release therapies for retinal conditions.

Notable figures affiliated with Glaukos include its founders and key investors who have significantly contributed to its growth and innovation. The company has achieved several milestones, including the development of the first FDA-approved micro-invasive glaucoma surgery (MIGS) device. Glaukos' impact on the ophthalmic field is profound, providing groundbreaking treatment alternatives that have improved the quality of life for patients globally. Their continued focus on research and development ensures they remain at the forefront of ophthalmic medical technology.